The pharmaceutical industry has entered a new era of innovation, with major drugmakers committing unprecedented capital to harness artificial intelligence for accelerating drug discovery and development. Leading companies including Eli Lilly, Merck, and Novo Nordisk have announced billion-dollar collaborations with technology giants—NVIDIA, Google Cloud, OpenAI, and AWS—signaling an industry-wide shift from experimental pilots to permanent AI infrastructure.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...
Contact us
Questions, corrections, or ideas? Send us a message here. We aim to reply by email within 24 hours.
Thank you. Your message has been sent. We aim to reply by email within 24 hours.Please enter your email address and a message.We could not send your message. Please try again in a little while.